Background: Maraviroc is the first CCR5 antagonist and only oral entry inhibitor approved for the treatment of HIV type-1 infection. Maraviroc is extensively metabolized, primarily by cytochrome P450 3A4 and hence its pharmacokinetics might be affected by impaired hepatic function. The objective of this study was to evaluate the pharmacokinetics of maraviroc in subjects with mild or moderate hepatic impairment compared with subjects with normal hepatic function. Safety and tolerability were also assessed. Methods: This was an open-label, non-randomized, single-centre, parallel-group study. A total of 24 subjects with mild (n=8) or moderate (n=8) hepatic impairment, or normal hepatic function (n=8) received a single dose of 300 mg maraviroc. Results: Relative to those with normal hepatic function, the geometric mean ratio (90% confidence interval) for
the maximum observed plasma concentration (C max ) of maraviroc was 111% (74.6-166) and 132% (89. for those with mild and moderate hepatic impairment, respectively; the area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC last ) was 125% (84.7-185) and 146% (100-212); oral clearance was 89% (53.2-150) and 83% (49.2-139); and renal clearance was 94% (70.5-126) and 131% (98.6-173), respectively. Maraviroc was well tolerated in all subjects. Conclusions: Although differences in maraviroc pharmacokinetics were noted in subjects with hepatic impairment compared with those with normal hepatic function, these do not currently support a dose modification. The single 300 mg dose of maraviroc was well tolerated by subjects with normal and impaired hepatic function.
The influence of hepatic disease on the safety and pharmacokinetics of antiretroviral agents is a field of increasing importance given the known high rates of coinfection with HIV and hepatitis virus B or hepatitis C virus (HCV) [1] [2] [3] , the increasing incidence of non-alcoholic fatty liver disease and hepatosteatitis in the general population [4] , which has been linked to age, obesity, type-2 diabetes and insulin resistance [5, 6] , and an increasing incidence of both alcoholic and non-alcoholic cirrhosis [7] . A significant incidence of hepatosteatitis has also been observed in HIV-HCVcoinfected patients with similar risk factors to those seen in the general population [8] .
Maraviroc is the first approved CCR5 antagonist and currently the only available oral HIV type-1 (HIV-1) entry inhibitor. Maraviroc acts by binding to the human CCR5 chemokine receptor that acts as an essential coreceptor for CCR5-tropic HIV-1, initiating a conformational change that prevents subsequent attachment to viral gp120 [9] . Maraviroc has demonstrated significant and durable virological and immunological efficacy in both treatment-experienced [10, 11] and treatmentnaive patients [12] infected with obligate CCR5-tropic (R5) HIV-1.
At steady state, 300 mg twice-daily maraviroc is associated with a maximum observed plasma concentration of maraviroc (C max ) and 12 h area under the concentrationtime curve (AUC 12 ) of approximately 900 ng/ml and 2,900 ng•h/ml, respectively, in healthy volunteers. Peak plasma concentrations generally occur within 0.5-4 h post-dose.
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Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment [14] . Metabolism by cytochrome P450 (CYP)3A4 is the major clearance route for maraviroc [15, 17] , with renal clearance (CL R ) accounting for <25% of total clearance [15] . Maraviroc does not inhibit any of the major CYPs [17, 18] . Maraviroc has also been shown not to induce CYP3A4 or inhibit/induce glucouronidation based on its lack of effect on the pharmacokinetics of midazolam [18] , ethinylestradiol [18] and 6 β-hydroxycortisol/cortisol ratios [19] . Hepatic damage and disease might affect CYP enzyme activities [20] [21] [22] [23] [24] [25] . It is anticipated that maraviroc pharmacokinetics might therefore be altered in patients with hepatic impairment. To address this, the following study was undertaken to examine the effect of mild and moderate hepatic impairment on the plasma pharmacokinetics of maraviroc in HIVnegative subjects.
Methods

Study design and subjects
An open-label parallel group study evaluated the pharmacokinetics, safety and tolerability of a single dose of maraviroc (300 mg) in HIV-negative subjects aged 18-70 years with mild or moderate hepatic impairment or normal hepatic function. All eligible subjects had to have a body weight >50 kg and a body mass index of approximately 18-30 kg/m 2 . Major exclusion criteria for all subjects were any condition potentially affecting drug absorption, a positive urine drug screen, pregnancy or nursing motherhood, the use of tobacco or nicotine-containing products in excess of the equivalent of five cigarettes per day, treatment with an investigational drug within the preceding 4 months and the use of prescription or non-prescription drugs, vitamins or dietary supplements (excluding necessary concomitant medications for hepatically impaired patients) within the previous 7 days or use of herbal supplements within the previous 28 days.
Subjects with normal liver function were healthy by medical history and examination, and free of any condition that might significantly affect the absorption of maraviroc. The normal hepatic function group was matched for sex, age (within 5 years) and weight (within 10 kg) with hepatically impaired subjects. Heavy alcohol use within the previous 6 months (females >14 drinks/week and males >21 drinks/week, where 1 drink was defined as 150 ml wine or 360 ml beer or 45 ml spirits) was an exclusion criterion for subjects within this group.
Subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment [26] were required to have a diagnosis of stable hepatic impairment caused by cirrhosis that was not secondary to other diseases, as confirmed and documented by biopsy or by other means. Breath alcohol tests at screening and pre-dose were required to be negative, although a history of alcohol abuse was permitted. All enrolled subjects were required to have normal creatinine clearance. Exclusion criteria for the two hepatic impairment groups included hepatic carcinoma, hepatorenal syndrome or life expectancy <1 year, transaminases >4× the upper limit of normal, history of portacaval shunt surgery, history of gastrointestinal haemorrhage and signs of significant hepatic encephalopathy.
The study consisted of a screening visit at up to 4 weeks pre-dose, a study period involving a single dose of 300 mg maraviroc and a follow-up visit 7-10 days post-dose. Screening evaluations included medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and laboratory safety tests. These procedures were repeated prior to dosing, 24 h postdosing and at the follow-up visit. Pregnancy tests were also conducted for females of child-bearing potential at screening and prior to dosing. Subjects were admitted to the unit on day 0, and fasted for at least 8 h prior to receiving maraviroc between 7.00 am and 10.00 am on day 1. Maraviroc was administered as a single dose of two 150 mg tablets taken with 240 ml water. No food or drink was permitted for the first 4 h post-dose and subjects remained in the unit for 24 h post-dose, returning for their 48 and 72 h evaluations and again for their follow-up visit 7-10 days post-dose.
Plasma samples for maraviroc assay were taken immediately pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 h post-dose. Urine for maraviroc assay was collected pre-dose and up to 24 h post-dose. Adverse events were monitored throughout the study.
The study was conducted at a single clinical site in Germany (Apex Research, GmbH, Munich, Germany) and in compliance with the ethical principles originating from the Declaration of Helsinki and all International Conference on Harmonisation Good Clinical Practice guidelines. Written informed consent was obtained from all subjects before initiation of protocol-specified procedures. The study protocol and informed consent documentation was reviewed and approved by the Independent Ethics Committee of the investigational centre. All applicable local regulatory requirements were followed.
Maraviroc assays
Concentrations of maraviroc in heparinized plasma samples were determined by a validated high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method by Tandem Labs (West Trenton, NJ, USA). In brief, human plasma (0.050 ml) was mixed with a maraviroc-D5 internal standard in acetonitrile and vortex-mixed. Following centrifugation, an aliquot (0.010-0.020 ml) was injected into the HPLC system. Chromatographic separation was achieved using a Fluophase PFP column (4.6×50 mm, 5 µm; Thermo Electron Corporation, Pittsburgh, PA, USA) and a mobile phase consisting of 80:20 v:v acetonitrile:25 mM ammonium acetate in aqueous 0.2% formic acid at a flow rate of 1 ml/min. The analytes were detected using an Applied Biosystem Sciex API 4000 LC/MS/MS system (MDI SCIEX, Concord, ON, Canada) operating in positive TurboIonSpray ® mode. The transition ions m/z 269→155 and 283→169 were monitored for maraviroc and maraviroc-D5, respectively. The linear range of quantitation for maraviroc was 0.500-500 ng/ml plasma, with a lower limit of quantitation (LLQ) of 0.500 ng/ml. The betweenday assay accuracy (%RE) ranged from -3% to 6.2% and the between-day assay precision (CV [%]) was <6.0%.
Concentrations of maraviroc in urine were determined by a validated HPLC-MS/MS method by Tandem Labs. In brief, human urine (0.050 ml) was mixed with blank human Na 2 EDTA plasma (0.050 ml) and assayed as described earlier for concentrations of maraviroc in plasma. The urinary quanatitation range for maraviroc was 5-5,000 ng/ml urine with an LLQ of 5 ng/ml. The %RE ranged from -11.6% to 0% and CV (%) was <6.1%.
Pharmacokinetic methods
Pharmacokinetic analyses were performed in WinNonlin ® (Pharsight ® , St Louis, MO, USA). The C max , time to C max (T max ) and urinary excretion of unchanged maraviroc over 24 h as a percentage of dose (Ae 24 %) were determined by direct observation. T 1/2 , area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC last ) or extrapolated to infinite time (AUC ∞ ), CL R and oral clearance values (CL/F) were determined by standard formulae from observed data. T 1/2 was only reported if the terminal log/linear phase could be adequately determined (that is, if at least three data points were available, r 2 was at least 0.9 and the duration over which the T 1/2 was estimated was at least two half-lives). If T 1/2 could not be reported, the dependent parameters AUC ∞ and CL/F were also not reported. In addition, AUC ∞ was only reported if the extrapolated area after the last data point did not exceed 20% of the total area.
Statistical methods
A sample size of eight subjects in each group was estimated to provide a 90% confidence interval (CI) of ±0.233 and ±0.299 on the natural log scale for AUC ∞ and C max , respectively, with 80% coverage probability. Assuming no change, it was estimated that the 90% CI for AUC ∞ and C max would be 79.2-126.2% and 74.2-134.9%, respectively. Assuming a twofold increase, it was estimated that the 90% CI for AUC ∞ and C max would be 158.4-252.5% and 148.3-269.7%, respectively. The common sd (natural log scale) of 0.232 and 0.298 for AUC ∞ and C max , respectively, was calculated using the within-subject variation for 24 h area under the concentration-time curve (AUC 24 h ; 0.054) and C max (0.089) obtained from the analysis of a previous study of maraviroc pharmacokinetics in healthy Asian and Caucasian patients (study A4001038; Pfizer, unpublished data).
Statistical analyses were performed in SAS ® version 8.2 (Cary, NC, USA). One-way analysis of variance was performed on log-transformed C max , AUC ∞ , AUC last , CL/F and CL R and on untransformed T max, comparing each hepatic impairment group to the normal hepatic function group, including hepatic group as a factor. Age, weight and gender were included as covariates in the analysis to account for some intersubject variability.
Results
A total of 18 men and 6 women between the ages of 39 and 66 years were enrolled. All subjects were Caucasian. Each study group (normal hepatic function, mild hepatic impairment and moderate hepatic impairment) comprised six males and two females and all subjects completed the study. Demographic and baseline characteristics are shown in Table 1 .
No subject in the normal hepatic function group received concomitant medications during the study. Five subjects in the mild impairment group and five subjects in the moderate impairment group received one or more concomitant medications, including acetylsalicylic acid, alfuzosin, allopurinol, bisoprolol, furosemide, hedera helix, ibuprofen, insulin, metoprolol, olmesartan, pantoprazole, propanolol, ramipril, spironolactone, thomapyrin N or xipamide.
The mean pharmacokinetic profiles of single-dose maraviroc in subjects with normal hepatic function and mild or moderate hepatic impairment are summarized in Figure 1 and Table 2. Table 2 also shows the geometric mean ratios (GMR) and 90% CI for key pharmacokinetic parameters in the hepatically impaired groups versus the normal hepatic function group.
Maraviroc plasma concentrations were generally higher for subjects with hepatic impairment relative to those with normal hepatic function. GMRs for C max and AUC last were 111% and 125%, respectively, for subjects with mild hepatic impairment compared with subjects with normal hepatic function, and 132% and 146%, respectively, for subjects with moderate hepatic impairment compared with subjects with normal hepatic function. CL/F and CL R were similar for subjects with mild hepatic impairment and those with normal hepatic function. Mean CL R was higher and mean CL/F was lower in subjects with moderate hepatic impairment compared with those with normal hepatic function ( Table 2) . T max and T 1/2 were similar across all three subject groups.
There were a total of 10 adverse events recorded in 8 subjects (3 normal hepatic function, 3 mild hepatic impairment and 2 moderate hepatic impairment), of which 7 events in 5 subjects (3 normal hepatic function and 2 mild hepatic impairment) were considered as treatment-related. Treatment-related events comprised abnormal sensation in the eye (n=1), fatigue (n=2), dizziness (n=3) and headache (n=1). All treatment-related adverse events were reported as mild in nature. No deaths and no withdrawals occurred in this study. There were no treatment-related serious adverse events, although one subject with moderate hepatic impairment and with pre-existing cardiovascular disease was hospitalized 8 days post-dose for unstable angina pectoris, which was considered unrelated to study treatment. No clinically significant changes in laboratory safety tests, physical examinations, vital signs or ECG results were observed.
Discussion
This study was designed to assess the effect of mild and moderate hepatic impairment on maraviroc pharmacokinetics and to identify whether a dosing adjustment would be needed in this population. In accordance with the US Food and Drug Association guidance on assessing the pharmacokinetics of agents in patients with impaired hepatic function [27] , a single dose of maraviroc was chosen because maraviroc has time-independent pharmacokinetics and, as such, single-dose data are predictive of multiple dose data. In particular, the AUC ∞ following a single dose of maraviroc is expected to be equivalent to AUC τ (AUC over the dosing interval) at steady-state. The study was conducted in non-HIV-infected subjects to enable the effect of changes in liver function to be assessed without being confounded by drug interactions with coadministered antiretroviral therapies. As is usual for this type of study, the cirrhotic patients chosen were classed as Child-Pugh A or B; however, data from this population might not necessarily be representative of the effects in subjects whose hepatic impairment is the result of other causes. This study did not include patients with severe hepatic impairment; however, it should be noted that an extensive drug interaction programme has been conducted with maraviroc, where the effects of potent CYP3A4 inhibitors have been assessed. In particular, the coadministration of boosted protease inhibitors with maraviroc has been shown to cause a marked increase in maraviroc AUC 12 h of up to 10-fold [28, 29] , which is considered to represent practically complete abolishment of non-renal maraviroc clearance. Halving of the dose of maraviroc (to 150 mg twice daily) when coadministered with potent CYP3A4 inhibitors, such as boosted protease inhibitors (not including tipranavir), appears to result in acceptable safety and efficacy, and is the approved maraviroc dosage in regimens containing potent CYP3A4 inhibitors in both the USA and the European Union. Although theoretically these data represent the worst case for hepatic impairment, it should be remembered that CL R is not reduced by the coadministration of potent metabolic inhibitors, and hence the kidneys might represent an important escape mechanism for maraviroc. By contrast, patients with severe hepatic impairment often have reduced renal function [30] , and hence this escape mechanism might also be severely limited.
With these caveats, administration of maraviroc as a single oral dose of 300 mg to subjects with mild or moderate hepatic impairment was found to be safe and well tolerated, and resulted in mean AUC last values that were 25% and 46% higher, respectively, than exposure in subjects with normal hepatic function. Smaller differences in C max were also observed. Hepatic impairment did not appear to affect T max or T 1/2 . The increases in exposure with increasing degree of hepatic impairment were associated with decreasing mean CL/F, although minimal difference was observed between subjects with mild (Child-Pugh A) hepatic impairment and those with normal hepatic function. Mean CL R appeared to be higher in subjects with moderate hepatic impairment compared with those with mild hepatic impairment and normal hepatic function. It is unclear whether this is a consequence of increased hepatic impairment (possibly a compensatory effect) or artefact, or indeed to what extent this apparent higher renal clearance might have limited the effect of the hepatic impairment on maraviroc exposure in this group.
The intersubject variability observed in the study was moderate with CV (%) values for C max and AUC parameters ranging from 26.8% to 53.0%. This variability is consistent with that observed in previous maraviroc studies [15, 18, 19, 28, 29, 31] . Although this study was conducted with a single dose, maraviroc exhibits very little accumulation on multiple dosing [19] , and hence these exposures are expected to be relevant to the clinical situation. The mean AUC parameters observed in this study ranged from 1,815 ng•h/ml to 2,621 ng•h/ml. The mean AUC τ estimated in the MOTIVATE 1 and 2 studies, in treatment-experienced HIV-infected patients receiving 300 mg twice daily maraviroc was 1,581 ng•h/ ml, and the mean AUC τ in patients receiving 150 mg twice daily maraviroc (with potent CYP3A4 inhibitors) was 2,847 ng•h/ml [32] . Therefore, the exposures seen in this study are within the range of exposures seen in large clinical studies with maraviroc, where adverse events in a highly treatment-experienced patient population receiving maraviroc with other antiretrovirals were similar to the placebo comparator arm [10, 33] .
Although these data do not suggest that the differences seen here are clinically relevant in the general HIVinfected population, long-term safety data are lacking in the hepatically impaired population. Furthermore, it should be emphasized that this study, although providing pharmacokinetic data to investigate the potential for hepatic impairment to affect maraviroc exposure and hence assess whether dose adjustment is appropriate, was not intended to address directly the issue of maraviroc safety.
In conclusion, the increases in maraviroc exposure seen in subjects with mild to moderate hepatic impairment do not currently support a recommendation for dose adjustment, and a single dose of 300 mg maraviroc was well tolerated in this population. However, physicians should be mindful of the lack of long-term safety data in mild-to-moderate impairment, and the lack of safety and pharmacokinetic data in severe impairment when considering the use of maraviroc in patients with liver-related conditions.
